Phase 3 N=375 A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Primary Fibromyalgia
Primary: Newly Emergent Adverse Events — 77; 132 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=847 Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
COVID-19
Primary: Geometric Mean of Area Under the Curve (AUC) of Antibody Against WA-1 S2-P for Cohort 1 — 2940.97; 26101.97; 14223.28; 2926.70 Arbitrary Unit*1/dilution
Phase 2 N=432 Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Advanced Cutaneous Squamous Cell Carcinoma
Primary: Overall Response Rate (ORR) by Independent Central Review — 50.8; 44.9; 46.4; 61.9 percentage of participants
N/A N=78 HIV-Related Stigma Intervention for Malaysian Clinicians
Hiv
Primary: Acceptability of Intervention — 4.22; 4.72; 4.45 score on a scale
Phase 4 N=139 FAsenra Safety Trial in India
In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
Primary: Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs — 44; 5; 43; 1 Participants
Phase 2 N=52 Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
Prostate Cancer
Primary: Assess the Efficacy of Radium-223 in Terms of Radiological rPFS — 5.53 months
N/A N=48 Alcohol Use and Chronic Pain Among Primary Care Patients
Alcohol Drinking · Chronic Pain
Primary: Alcohol Time Line Followback (30)- Heavy Drinking Episode Days in the Past 30 Days — 7.9; 4.3 heavy drinking days
N/A N=51 Partners for Pain & Wellbeing Equity: A Randomized Trial of Community Supported Complementary and Integrative Health Self-management for Back Pain
Neck Pain · Low Back Pain · Chronic Pain
Primary: Recruitment Feasibility: # of Enrolled Participants — 51 Participants
Phase 3 N=110 A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
Growth Hormone Deficiency in Children
Primary: Height Velocity — 10.5; 11.0 Cm/year (centimeter per year)
Phase 3 N=168 NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Primary: Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 66 — 0.2964; 25.0557 scores on a scale — p=0.00000001
Phase 4 N=129 Pre-incision Versus Post-incision Local Anesthetic During Robotic Sacrocolpopexy
Pain, Postoperative
Primary: Likert-pain Scale Score on Postoperative Day One — 2.94; 3.27 units on a scale
N/A N=40 Symmetric vs Asymmetric BLR Recession in Management of Basic IXT With Ocular Dominance
Intermittent Exotropia
Primary: Ocular Alignment at Distant Fixation — 5.8; 1.1 prism diopter
N/A N=81 Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Chronic Kidney Disease
Primary: Skin Autofluorescence Levels at 6 Months — 3.7; 3.8 Arbitrary units
Phase 2 N=40 Galcanezumab for Vestibular Migraine
Vestibular Migraine
Primary: Change in VM-PATHI (Vestibular Migraine-Patient Assessment Tool and Handicap Inventory) Score From Baseline to Month 4 — -14.8; -5.1 score on a scale
N/A N=565 Single-Session Intervention Targeting Self-Injurious Behavior in Adolescents
Nonsuicidal Self Injury · Self Hatred · Suicidal Thoughts
Primary: Nonsuicidal Self-injury Frequency in the Past 3 Months — 15.81; 13.93; 22.72; 23.85 Nonsui behaviors (i.e., number of times)